"These drugs have the potential to change societies, not just individuals." — Michael Le Page, New Scientist, March 29, 2025 ...

The Mounjaro (tirzepatide) product information warns that inflammation of the pancreas (acute pancreatitis) is an uncommon ...

Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The global health landscape is evolving with Brazil battling bird flu-related trade restrictions, Nestle USA eliminating ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -4.99%) were lower by 4% as of 11 a.m. ET today. The move comes ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...